ViiV Healthcare to Present Groundbreaking HIV Research at Major Global Conferences
Table of Contents
ViiV Healthcare will showcase over 60 research abstracts at the 20th European AIDS Conference (EACS) in Paris and IDWeek 2025 in Atlanta, signaling continued advancements in HIV treatment and prevention. The presentations, set to take place in October 2025, will highlight the efficacy of existing therapies and the potential of the company’s developing pipeline.
Expanding the Horizon of HIV Care
The upcoming presentations underscore ViiV Healthcare’s dedication to addressing the evolving needs of individuals impacted by HIV. According to a company release, the breadth of data presented at both EACS and IDWeek will reinforce the effectiveness of current therapies and offer a glimpse into promising future innovations.
“The breadth of our data presented at EACS and IDWeek reinforce the effectiveness of our therapies,the potential promise of our pipeline and our unwavering commitment to meeting the evolving needs of those impacted by HIV,” a senior official stated.
ViiV Healthcare is preparing to present a ample body of research at two major conferences, the 20th European AIDS Conference (EACS) in Paris, October 15-18, and IDWeek 2025 in Atlanta, October 19-22. The company will present over 60 research abstracts, focusing on both existing and emerging therapies for HIV. This extensive presentation aims to demonstrate the continued effectiveness of current HIV treatments and offer a preview of potential future innovations.
CLARITY Study: Empowering Patient-Centered Treatment
A key focus of the presentations will be the findings from the CLARITY study.This research compares single-dose injections of cabotegravir and lenacapavir, two long-acting medications, and provides valuable insights into both patient and provider preferences.
The study aims to empower informed decision-making regarding treatment options, building upon the growing body of real-world evidence supporting long-acting HIV treatment and prevention strategies. This is especially significant as patient adherence remains a critical factor in successful HIV management.
The CLARITY study directly addresses the challenges of treatment adherence, a long-standing issue in HIV management. by comparing cabotegravir and lenacapavir, both long-acting injectable medications, the study seeks to understand which option best suits individual patient and provider needs. The results will contribute to more personalized treatment plans,potentially leading to improved viral suppression and overall health outcomes. ViiV Healthcare’s investment in these long-acting therapies represents a significant step forward in simplifying HIV treatment regimens.
Conference Details and Future Outlook
The 20th European AIDS Conference will be held in Paris, France, from October 15-18. IDWeek 2025 will follow, taking place in Atlanta, Georgia, from October 19-22. These conferences represent crucial platforms for disseminating cutting-edge research and fostering collaboration within the global HIV community.
ViiV Healthcare’s robust presentation schedule demonstrates it’s ongoing commitment to innovation and its dedication to improving the lives of those living with and at risk of contracting HIV. The company’s continued investment in research and development promises to deliver even more effective and patient-friendly solutions in the years to come.
